1 / 7

Terbium-161 A Next-Generation Alternative to Lutetium-177

Terbium-161 (Tb-161) is an emerging radionuclide therapy that is gaining attention as a potential next-generation alternative to Lutetium-177 (Lu-177) for targeted cancer treatment. Tb-161 emits beta particles and Auger electrons, providing enhanced radiation precision with the potential for deeper tumor penetration and improved targeting of smaller cancer cells. Its unique properties make it a promising option for patients who may not respond as well to Lu-177, offering more effective treatment options in the realm of personalized nuclear medicine.<br>More information available at nuclearmedicin

Nuclearmedicinetherapy
Download Presentation

Terbium-161 A Next-Generation Alternative to Lutetium-177

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nuclear Medicine Centre FMRi Gurugram INDIA Dr. Ishita B Sen Terbium-161: A Next-Generation Alternative to Lutetium-177 www.nuclearmedicinetherapy.in

  2. What is Terbium-161? • A novel radionuclide emitting beta particles, conversion electrons, and Auger electrons. • Comparison with Lutetium-177: • Similar half-life (~6.9 days) but with additional electron emissions, potentially enhancing therapeutic efficacy. • Therapeutic Potential: • Enhanced DNA damage in cancer cells, especially effective against micrometastases.​

  3. Advantages Over Lutetium-177 • Enhanced Efficacy: • Auger and conversion electrons deliver higher linear energy transfer, leading to increased tumor cell kill. • Improved Targeting: • Effective against microscopic tumors and single cancer cells. • Imaging Capabilities: • Emits gamma rays suitable for SPECT imaging, facilitating therapy monitoring.​

  4. Clinical Developments • VIOLET Trial: • Phase I/II trial evaluating Terbium-161-PSMA-I&T in metastatic castration-resistant prostate cancer (mCRPC) patients. • Preclinical Success: • Studies indicate 2–4 times higher absorbed doses to microscopic tumors compared to Lutetium-177. • Global Collaborations: • Partnerships between institutions like Peter MacCallum Cancer Centre and Isotopia are advancing clinical research. ​

  5. Production and Availability • Production Method: • Generated by neutron irradiation of enriched gadolinium-160 targets in nuclear reactors. • Challenges: • Limited availability due to complex production and purification processes. • Future Outlook: • Efforts are underway to scale up production to meet clinical demand. ​

  6. Conclusion • Terbium-161 offers promising advantages over Lutetium-177, including higher energy emissions and improved targeting of micrometastases. • Clinical Implications: • Ongoing trials like VIOLET are crucial to establishing its efficacy and safety profile. • Looking Ahead: • With advancements in production and clinical validation, Terbium-161 could become a cornerstone in targeted radionuclide therapy.​

  7. For more information talk to Dr. Ishita B Sen today. dr.ishitasen@nuclearmedicinetherapy.in +91 8700 668 431 www.nuclearmedicinetherapy.in

More Related